A5035590576- Ovarian cancer diagnosis and treatment
- Estrogen and related hormone effects
- Endometrial and Cervical Cancer Treatments
- Cancer Genomics and Diagnostics
- Glycosylation and Glycoproteins Research
- Breast Cancer Treatment Studies
- Monoclonal and Polyclonal Antibodies Research
- HER2/EGFR in Cancer Research
- Reproductive System and Pregnancy
- Advanced Breast Cancer Therapies
- Cancer Cells and Metastasis
- Endometriosis Research and Treatment
- Genetic factors in colorectal cancer
- Cancer Treatment and Pharmacology
- Breast Lesions and Carcinomas
- Cervical Cancer and HPV Research
- Galectins and Cancer Biology
- Immunotherapy and Immune Responses
- Growth Hormone and Insulin-like Growth Factors
- Global Cancer Incidence and Screening
- Reproductive Biology and Fertility
- Thyroid Disorders and Treatments
- BRCA gene mutations in cancer
- PARP inhibition in cancer therapy
- Molecular Biology Techniques and Applications
University Hospital Heidelberg
2016-2025
Heidelberg University
2016-2025
University Hospital Ulm
2024-2025
National Center for Tumor Diseases
2016-2025
German Cancer Research Center
2023-2025
Klinik für Frauenheilkunde
2012-2025
Universitäts Frauenklinik
2016-2024
Frauenklinik Heidelberg
2016-2023
Ludwig-Maximilians-Universität München
2013-2022
LMU Klinikum
2014-2022
Mammalian Target of Rapamycin Complex 1 (mTORC1) is activated by growth factor-regulated phosphoinositide 3-kinase (PI3K)/Akt/Rheb signalling and extracellular amino acids (AAs) to promote proliferation. These AAs induce translocation mTOR late endosomes lysosomes (LELs), subsequent activation via mechanisms involving the presence intralumenal AAs, interaction between mTORC1 a multiprotein assembly containing Rag GTPases heterotrimeric Ragulator complex. However, which control these...
There is partially conflicting evidence on the influence of steroid hormones estrogen (E) and progesterone (P) development ovarian cancer (OC). The aim this study was to assess expression receptor isoforms ER-α/-β PR-A/-B in OC tissue analyze its impact clinical pathological features patient outcome. 155 patients were included who had been diagnosed treated between 1990 2002. Patient characteristics, histology follow-up data available. determined by immunohistochemistry. positive for 31.4%...
Abstract Purpose: Endometrioid ovarian carcinoma (ENOC) is generally associated with a more favorable prognosis compared other carcinomas. Nonetheless, current patient treatment continues to follow “one-size-fits-all” approach. Even though tumor staging offers stratification, personalized treatments remain elusive. As ENOC shares many clinical and molecular features its endometrial counterpart, we sought investigate The Cancer Genome Atlas–inspired (EC) subtyping in cohort of ENOC....
Obstetrics and gynecology (OB/GYN) is an essential medical field that focuses on women's health. Universities aim to provide high-quality healthcare services women through comprehensive education of students. In Germany, undergoing a phase restructuring towards the implementation competency-based learning. The objective current survey was gain insights into teaching methods, resources, challenges at German universities in OB/GYN. This aims document state derive potential suggestions for...
TPS620 Background: Current guidelines limit routine breast cancer (BC) follow-up to clinical examinations and imaging. This is based on the results of two large cohort studies conducted in 1980s that showed no improvement overall survival (OS) by an intensified screening for distant metastases. Thus, imaging metastases should currently only be performed patients with specific symptoms. To detect relapse a pre-symptomatic stage, we suggest evaluation liquid biopsy-guided surveillance,...
Decidual macrophages (DM) are the second most abundant population in fetal-maternal interface. Their role has been so far identified as being local immuno-modulators favoring maternal tolerance to fetus. Herein we investigated tissue samples from 11 cases of spontaneous miscarriages and 9 elective terminations pregnancy. Using immunohistochemistry dual immunofluorescence have demonstrated that DM significantly increased. Additionally, noted a significant up-regulation macrophage FasL...
Tumour cells can use strategies that make them resistant to nutrient deprivation outcompete their neighbours. A key integrator of the cell's responses starvation and other stresses is amino-acid-dependent mechanistic target rapamycin complex 1 (mTORC1). Activation mTORC1 on late endosomes lysosomes facilitated by amino-acid transporters within solute-linked carrier 36 (SLC36) SLC38 families. Here, we analyse functions SLC36 family member, SLC36A4, otherwise known as proton-assisted...
Abstract Neoadjuvant chemotherapy (NACT) in early breast cancer (EBC) enables vivo sensitivity testing and less radical surgery as compared to primary adjuvant (ACT). The aim of our study is illustrate trends systemic treatment EBC. analyzed usage time for patients with EBC treated at 104 German units between January 2008 December 2017. data were obtained through a quality‐controlled benchmarking process. Altogether, 124 084 included, whom 46 279 (37.3%) received chemotherapy. For 44 765...
Follicle stimulating hormone receptor (FSHR) and luteinizing (LHCGR) were demonstrated to impact upon survival of patients suffering from epithelial ovarian cancer (EOC). Though structure wise the G-protein coupled estrogen (GPER/GPR30) is related FSHR/LHCGR, its prognostic in EOC remains controversial. We recently found that FSHR negative represent a specific subgroup may behave differently respect both treatment response prognosis. Hence, current study aimed analyze how GPER interact with...
Since BRCA1 associated breast cancers are frequently classified as hormone receptor negative or even triple negative, the application of endocrine therapies is rather limited in these patients. Like receptors that bind to estrogen progesterone, thyroid (TRs) members nuclear superfamily. TRs might be interesting biomarkers - especially absence classical receptors. The current study aimed investigate whether may specifically expressed cancer cases and they prognostic significance patients...
Abstract Background Cyclin E1 (CCNE1) is a potential predictive marker and therapeutic target in tubo‐ovarian high‐grade serous carcinoma (HGSC). Smaller studies have revealed unfavorable associations for CCNE1 amplification overexpression with survival, but to date no large‐scale, histotype‐specific validation has been performed. The hypothesis was that high‐level of overexpression, as well combination the two, are linked shorter overall survival HGSC. Methods Within Ovarian Tumor Tissue...
In recent years, new targeted therapies have been developed to treat patients with hormone receptor-positive (HR+)/human epidermal growth factor receptor 2-negative (HER2-) breast cancer. Some of these not just become the therapy standard but also led significantly longer overall survival rates. The cyclin-dependent kinase 4 and 6 inhibitors (CDK4/6i) therapeutic for first-line therapy. Around 70 - 80% are treated a CDK4/6i. number biomarkers associated progression, clonal selection or...
Zusammenfassung Für Patientinnen wie auch Patienten mit hormonrezeptorpositivem (HRpos)/Human epidermal growth factor receptor 2- negativem (HER2neg) Mammakarzinom wurden in den letzten Jahren einige neue, zielgerichtete Therapien eingeführt. Einige dieser Behandlungen konnten sich nicht nur als neuer Therapiestandard etablieren, sondern führten zu einem signifikant verlängerten Gesamtüberleben. Insbesondere die Cyclin-dependent Kinase 4 and 6 Inhibitors (CDK4/6i) haben der ersten...
Abstract As part of the COGNITION diagnostic registry program, residual tumor material after neoadjuvant therapy (NAT) patients with early breast cancer (eBC), who are still at high-risk for relapse NAT, is analyzed by next generation sequencing to identify biomarkers and actionable alterations. This strategy aims stratify subsequent genomics-guided therapies reduce significant risk metastatic dissemination hence improve disease-free survival. COGNITION-GUIDE a multicenter umbrella...
Abstract With around 70000 new cases every year, breast cancer (BC) continues to be the most prevalent form of cancer. Hormone receptor-positive, HER2-negative (HR+/HER2−) BC is common type and accounts for 70% early (eBC). The development drugs in recent years has significantly improved survival patients with eBC. Alongside established endocrine therapy (ET) options such as tamoxifen, aromatase inhibitors (AI), GnRH analogs, additional treatment CDK 4/6 (abemaciclib ribociclib) PARP...
Background: The anti-tumor response of the immune system is pivotal for treating triple-negative breast cancer (TNBC), particularly as targeted therapies are limited. However, impact immune-modulating factors such application granulocyte-stimulating (G-CSFs) or infections, including febrile neutropenia, prophylactic therapeutical oral antibiotics (OABs), and need intravenous (IABs), on survival outcomes remains unclear. Methods: 1583 patients with early-stage TNBC enrolled in SUCCESS A C...